Investigating the Effectiveness of Eylea in Patients With Wet Age-related Macular Degeneration

• Status: Completed
• Trial end date: 2017-03-31
• Target enrollment: 0
• Participant gender: All

Summary

The study aims to investigate the effectiveness of Eylea in patients with wet age-related macular degeneration in routine clinical practice in Germany. The study is purely observational, only data from routine treatment are to be collected. The treatment and treatment conditions are solely at discretion of the treating physician.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer
• Collaborator: Regeneron Pharmaceuticals
• Treatments: Aflibercept

Criteria

Inclusion Criteria:

• Patients with wet wAMD treated with Eylea (in accordance with the local Summary of Product Characteristics, SPC).

• Written informed consent.

Exclusion Criteria:

• Exclusion criteria as listed in the local SPC.

• Scar, fibrosis, or atrophy involving the center of the fovea in the study eye.

• Any concomitant therapy with another agent to treat wet AMD in the study eye.